- Price
- $59.09
- Day
- +2.00%
- Mkt Cap
- $162.63M
- 52W Range
- $7.26 – $240.00
- Volume
- 172.8K
- Beta
- 3.36
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website enables families and caregivers to learn about, and register their interest in, t.
Read full article
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disor
Read full article
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanf.
Read full article